Sakar Healthcare Ltd (SAKAR) — share price & stock analysis

Market cap

₹1,807 Cr

P/E

59.3×

ROE

10.0%

vs own 10-yr valuation

91st pctile

Book value / share

₹146

EPS (TTM)

₹13.7

10-yr median P/E

39.6×

Revenue (FY26)

₹252 Cr

Profit after tax (FY26)

₹30 Cr

Weinstein stage

Stage 2 (56 weeks)

Data as of

1 July 2026

5 of the 6 things we track are currently moving the right way — nearly everything is pulling in the same direction.

Where the levels actually stand: ROCE 13% — decent; effectively no debt; margins near the top of their band. Momentum says which way things are moving; these say where they are.

Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double.

The market has pre-paid for growth that hasn’t arrived yet

Since Jun 2018, the stock is up 1,328% while earnings per share grew 341%. The difference is re-rating — investors paying more for the same rupee of profit.pricettm_eps

That works until it doesn’t: from here, earnings have to do the lifting, because the multiple has already done its part.

Today’s P/E of 59.3× means the market is paying up — this is the expensive end of its own 10-year history (91st percentile).pe_ratio

Price is the weekly close (₹). EPS is trailing-twelve-month profit per share, anchored on Screener's own snapshots; between snapshots it is filled from price ÷ P/E (an exact identity), and any fill straying more than 18% from the neighbouring snapshots is dropped rather than shown. The lower panel is the P/E — what the market pays per rupee of profit; the dotted line is its long-run median (39.6×).

An uptrend that has held for 56 weeks

Every stock cycles through the same four seasons — a flat base (stage 1), an advance (2), a top (3), a decline (4). Right now this one is in Stage 2: advancing, 56 weeks in, confirmed.stage

The price sits above its rising 200-day average (₹549 today) and its strength against the index is still improving — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200

Beating NIFTY 500 for 65 weeks — relative strength is the market’s live opinion, and right now it is on this stock’s side.rs_mansfield

What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200

Profits are at an all-time high

Over 12 years, sales went from ₹30.0 Cr to ₹252 Cr (about 19% a year), and profit from ₹2.0 Cr to ₹30.0 Cr.revenuenet_profit

Margins took a round trip — down to 19.5% in FY16, back to 27.4% now. The profit growth survived the squeeze.operating_profit

Sales exploded 42% last quarter — growth every single quarter for over 2 years

Mar 26 sales were ₹71.0 Cr, up 42% on the same quarter last year.revenue

That makes 10 quarters of growth in a row — this is a trend, not a blip.revenue

Margins are widening — 31% → 37% in a year

Of every ₹100 of sales, the company keeps ₹36.9 as operating profit (a year ago it kept ₹31.3).opm_pct

Zoom out and this is the page's quiet hero: annual operating margin bottomed at 22.7% in FY22 and has been rebuilt to 27.4% — that recovery, not sales alone, is what powers the profit growth elsewhere on this page.operating_profit

The gross margin barely moved (71% → 60%), so the change came from running costs — the business is getting more efficient as it scales.gpm_pctopm_pct

Profit exploded 83% — mostly from selling more

Mar 26 profit after tax was ₹11.0 Cr, up 83% year on year.net_profit

The profits are real — they turn into cash

Over the last 5 profitable years, the business reported ₹88.0 Cr of profit and collected ₹176 Cr of operating cash — about 200% conversion.operating_cash_flownet_profit

One asterisk on that strength: suppliers are being paid 60 days later than a year ago (93 → 153 days). Cash flattered by stretching payables is real cash — but it is borrowed timing, not extra earning power.payable_days

The cash cycle looks tighter — but it is supplier credit doing the work

One rupee now takes about 127 days to go out the door as materials and come back as collected cash — down from 163 days the year before.cash_conversion_cycle

Look inside the improvement, though: suppliers are being paid 60 days later (93 → 153 days), while inventory actually got heavier (193 → 207 days). Supplier credit is funding the cycle — useful, but not the same thing as customers paying faster.payable_daysinventory_days

The asset base keeps compounding — this company builds

The productive asset base has gone from ₹38.0 Cr (FY14) to ₹326 Cr, with another ₹4.0 Cr of capacity under construction right now.fixed_assetscwip

The build is bigger than the cash engine: investing outflows (₹111 Cr) exceeded operating cash (₹107 Cr) over the last 3 years — the difference comes from debt or shareholders.investing_cash_flowoperating_cash_flow

Almost no debt — this company cannot be killed by a bad year

For every ₹100 shareholders have put in (and left in), the company has borrowed ₹17 — total borrowings have grown from ₹24.0 Cr to ₹55.0 Cr over the window.borrowings

Every ₹100 kept in the business earns ₹13 — decent, not special

Return on capital employed is 13.0% (a year ago: 9.0%). This is the single best test of business quality: what the company earns on the money it keeps.roce_pct

Rising returns on capital while growing is the rarest combination in investing — it means the new projects earn more than the old ones.roce_pct

The owners aren’t moving

Promoters hold 52.9%, essentially unchanged. Foreign funds own 12.9%, domestic funds 11.3%.promoters_pctfiis_pctdiis_pct

A good business — the question is the price

The numbers are genuinely mixed, and the price already assumes the good news continues.

Best thing in the data: free cash flow rising (₹3.0 Cr → ₹21.0 Cr).operating_cash_flow

Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.

Straight answers from the data